Literature DB >> 3071193

Serum resistance and virulence of Escherichia coli isolated from turkeys.

M G Ellis1, L H Arp, S J Lamont.   

Abstract

Twenty-five strains of Escherichia coli isolated from turkeys were characterized for their serum resistance and virulence. An in vitro bactericidal assay was used to determine the serum resistance of E coli. Virulence was determined by survival time after IV inoculation of each strain into 3-week-old turkeys. Serum-resistant E coli strains were generally found to be virulent for turkeys, whereas serum-sensitive E coli strains were avirulent. Of the 25 strains, 18 strains were placed in the 2 categories of serum-resistant/virulent and serum-sensitive/avirulent. Five strains were serum-resistant and avirulent, and 2 strains were serum-sensitive and virulent. Serum resistance appears to be an important determinant of virulence for E coli in turkeys; however, the requirement for other virulence factors, in addition to serum resistance, was suggested by the finding that 5 serum-resistant strains were avirulent in turkeys.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071193

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  Relationship between the Tsh autotransporter and pathogenicity of avian Escherichia coli and localization and analysis of the Tsh genetic region.

Authors:  C M Dozois; M Dho-Moulin; A Brée; J M Fairbrother; C Desautels; R Curtiss
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Colonization of the respiratory tract by a virulent strain of avian Escherichia coli requires carriage of a conjugative plasmid.

Authors:  C A Ginns; M L Benham; L M Adams; K G Whithear; K A Bettelheim; B S Crabb; G F Browning
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Production of toxins (enterotoxins, verotoxins, and necrotoxins) and colicins by Escherichia coli strains isolated from septicemic and healthy chickens: relationship with in vivo pathogenicity.

Authors:  J E Blanco; M Blanco; A Mora; J Blanco
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 4.  Resistance to serum complement, iss, and virulence of avian Escherichia coli.

Authors:  L K Nolan; S M Horne; C W Giddings; S L Foley; T J Johnson; A M Lynne; J Skyberg
Journal:  Vet Res Commun       Date:  2003-02       Impact factor: 2.459

5.  pap-and pil-related DNA sequences and other virulence determinants associated with Escherichia coli isolated from septicemic chickens and turkeys.

Authors:  C M Dozois; J M Fairbrother; J Harel; M Bossé
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

Review 6.  Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns.

Authors:  S M Lutful Kabir
Journal:  Int J Environ Res Public Health       Date:  2010-01-12       Impact factor: 3.390

7.  Characterization of Escherichia coli isolated from cases of avian colibacillosis.

Authors:  B J Allan; J V van den Hurk; A A Potter
Journal:  Can J Vet Res       Date:  1993-07       Impact factor: 1.310

8.  Role of virulence factors in resistance of avian pathogenic Escherichia coli to serum and in pathogenicity.

Authors:  Melha Mellata; Maryvonne Dho-Moulin; Charles M Dozois; Roy Curtiss; Peter K Brown; Pascal Arné; Annie Brée; Clarisse Desautels; John M Fairbrother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Heparinase Is Essential for Pseudomonas aeruginosa Virulence during Thermal Injury and Infection.

Authors:  Nyaradzo Dzvova; Jane A Colmer-Hamood; John A Griswold; Abdul N Hamood
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

10.  Analysis of immune responses induced by avian pathogenic Escherichia coli infection in turkeys and their association with resistance to homologous re-challenge.

Authors:  Jean-Rémy Sadeyen; Pete Kaiser; Mark P Stevens; Francis Dziva
Journal:  Vet Res       Date:  2014-02-14       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.